ENZN Enzon Pharmaceuticals Inc

Price (delayed)

$0.309

Market cap

$22.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.04

Enterprise value

-$24.5M

Highlights
Enzon Pharmaceuticals's net income has shrunk by 64% QoQ but it has increased by 27% YoY
ENZN's quick ratio is up by 11% year-on-year but it is down by 2.2% since the previous quarter
The gross profit has plunged by 54% from the previous quarter and by 26% YoY
ENZN's revenue has dropped by 54% since the previous quarter and by 26% year-on-year

Key stats

What are the main financial stats of ENZN
Market
Shares outstanding
74.21M
Market cap
$22.93M
Enterprise value
-$24.5M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.67
Price to sales (P/S)
71.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-76.55
Earnings
Revenue
$320,000
EBIT
-$770,000
EBITDA
-$770,000
Free cash flow
-$758,000
Per share
EPS
-$0.04
Free cash flow per share
-$0.01
Book value per share
$0.05
Revenue per share
$0
TBVPS
$0.64
Balance sheet
Total assets
$47.47M
Total liabilities
$43.42M
Debt
$0
Equity
$4.05M
Working capital
$47.06M
Liquidity
Debt to equity
0
Current ratio
115.78
Quick ratio
115.68
Net debt/EBITDA
61.6
Margins
EBITDA margin
-240.6%
Gross margin
100%
Net margin
-240.9%
Operating margin
-242.8%
Efficiency
Return on assets
-5.9%
Return on equity
-54.1%
Return on invested capital
N/A
Return on capital employed
-1.6%
Return on sales
-240.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENZN stock price

How has the Enzon Pharmaceuticals stock price performed over time
Intraday
-7.84%
1 week
1.08%
1 month
6.59%
1 year
-53.88%
YTD
-9.78%
QTD
1.31%

Financial performance

How have Enzon Pharmaceuticals's revenue and profit performed over time
Revenue
$320,000
Gross profit
$320,000
Operating income
-$777,000
Net income
-$771,000
Gross margin
100%
Net margin
-240.9%
The operating income has plunged by 66% from the previous quarter but it has grown by 26% YoY
Enzon Pharmaceuticals's net income has shrunk by 64% QoQ but it has increased by 27% YoY
The gross profit has plunged by 54% from the previous quarter and by 26% YoY
ENZN's revenue has dropped by 54% since the previous quarter and by 26% year-on-year

Growth

What is Enzon Pharmaceuticals's growth rate over time

Valuation

What is Enzon Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.67
P/S
71.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-76.55
The company's EPS fell by 33% QoQ
The stock's price to book (P/B) is 128% more than its 5-year quarterly average of 2.7 and 4.2% more than its last 4 quarters average of 5.9
The equity has contracted by 41% YoY and by 17% from the previous quarter
ENZN's revenue has dropped by 54% since the previous quarter and by 26% year-on-year
The P/S is 45% above the last 4 quarters average of 53.6 and 44% above the 5-year quarterly average of 54.1

Efficiency

How efficient is Enzon Pharmaceuticals business performance
Enzon Pharmaceuticals's return on equity has shrunk by 67% YoY and by 29% QoQ
ENZN's return on assets is up by 21% year-on-year but it is down by 13% since the previous quarter

Dividends

What is ENZN's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Enzon Pharmaceuticals financials performed over time
Enzon Pharmaceuticals's total assets is 9% more than its total liabilities
ENZN's quick ratio is up by 11% year-on-year but it is down by 2.2% since the previous quarter
The current ratio has increased by 11% YoY but it has decreased by 2.3% from the previous quarter
ENZN's debt is 100% smaller than its equity
The equity has contracted by 41% YoY and by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.